AVR supply chain intelligence for Anteris Technologies Global Corp.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Anteris Technologies Global Corp. (AVR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NORTHCROSS-WEST-INDUSTRIAL-OWNER-LLC | NORTHCROSS-WEST-INDUSTRIAL-OWNER-LLC | 92% | The Lease has an initial term commencing September 1, 2026 and expiring August 31, 2037 and may be extended for two periods of 84 months each at market rent, subject to other terms and conditions set… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | Pursuant to the terms of the Agreement, the Company may offer and sell through TD Cowen, from time to time and at its sole discretion, shares of the Company’s common stock |
| V2VMEDTECH-INC | V2VMEDTECH-INC | 90% | The Company is required to pay a break fee of $400,000 to v2v, which will be used by v2v for continued development of the technology. |
| EW | Edwards Lifesciences Corporation | 72% | Reciprocal relationship from EW graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological … |
| EW | Edwards Lifesciences Corporation | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| ITGR | Integer Holdings Corporation | 72% | Reciprocal relationship from ITGR graph: Reciprocal relationship from AVR graph: he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any reven… |
| ITGR | Integer Holdings Corporation | 72% | he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any revenue from ESIA pursuant to the ESIA Agreement. As of December 31, 2024, we paid an … |
| LMAT | LeMaitre Vascular, Inc. | 72% | Reciprocal relationship from LMAT graph: Reciprocal relationship from AVR graph: ment No. 2 to Transition Services Agreement, dated December 19, 2022, among Anteris Technologies Ltd, Admedus Regen Pt… |
| LMAT | LeMaitre Vascular, Inc. | 72% | ment No. 2 to Transition Services Agreement, dated December 19, 2022, among Anteris Technologies Ltd, Admedus Regen Pty Ltd, Admedus Biomanufacturing Pty Ltd and LeMaitre Vascular, Inc. S-1 11/22/202… |
| MDT | Medtronic plc | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| 4C-MEDICAL-TECHNOLOGIES-INC | 4C-MEDICAL-TECHNOLOGIES-INC | 90% | The Supply and License Agreement with 4C (the "4C Agreement"), had an initial seven-year term that ended on June 1, 2025, and under its terms would automatically renew for successive one-year periods… |
| LEMAITRE-VASCULAR-INC | LEMAITRE-VASCULAR-INC | 90% | Such sales have historically been made principally to 4C Medical Technologies, Inc. ("4C") and, in prior periods, to LeMaitre Vascular, Inc. ("LeMaitre"), a distributor of medical products. |
| LMAT | LeMaitre Vascular, Inc. | 85% | Reciprocal relationship from LMAT graph: Reciprocal relationship from AVR graph: s determined that the activities of the business as reviewed by our Vice Chairman and Chief Executive Officer, who als… |
| LMAT | LeMaitre Vascular, Inc. | 85% | s determined that the activities of the business as reviewed by our Vice Chairman and Chief Executive Officer, who also serves as our chief operating decision maker, are one segment, being the develo… |
| MEDICAL-TECHNOLOGIES-INC | MEDICAL-TECHNOLOGIES-INC | 85% | s determined that the activities of the business as reviewed by our Vice Chairman and Chief Executive Officer, who also serves as our chief operating decision maker, are one segment, being the develo… |
| EW | Edwards Lifesciences Corporation | 72% | Reciprocal relationship from EW graph: Reciprocal relationship from AVR graph: Reciprocal relationship from EW graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR market… |
| EW | Edwards Lifesciences Corporation | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| ITGR | Integer Holdings Corporation | 72% | Reciprocal relationship from ITGR graph: Reciprocal relationship from AVR graph: he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any reven… |
| ITGR | Integer Holdings Corporation | 72% | he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any revenue from ESIA pursuant to the ESIA Agreement. As of December 31, 2024, we paid an … |
| MDT | Medtronic plc | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from AVR graph: Reciprocal relationship from MDT graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR mark… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | in January 2025, and we do not expect to receive any future revenue from LeMaitre. The Supply and License Agreement with 4C (the “4C Agreement”), had an initial seven-year term that ended on June 1, … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AVR-DEBT | Debt stack $3.7M | 90% | Market cache reports total debt of $3.7M. |
| AVR-DEBT-13803 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AVR-OWNER-L1-CAPITAL-PTY-LTD | L1 Capital Pty Ltd | 90% | 13F overlay lists L1 Capital Pty Ltd as top holder; 129 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ITGR | Integer Holdings Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| MDT | Medtronic plc | 100.00 | 1 | ['customer', 'supplier'] |
| EW | Edwards Lifesciences Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| SNNUF | Smith & Nephew plc | 50.00 | 2 | |
| ALC | Alcon Inc. | 50.00 | 2 | |
| SIBN | SI-BONE, Inc. | 50.00 | 2 | |
| ABT | Abbott Laboratories | 50.00 | 2 | |
| DXCM | DexCom, Inc. | 50.00 | 2 | |
| ELUT | Elutia Inc. | 50.00 | 2 | |
| GWW | W.W. Grainger, Inc. | 50.00 | 2 | |
| ISRG | Intuitive Surgical, Inc. | 50.00 | 2 | |
| MASI | Masimo Corporation | 50.00 | 2 | |
| SSII | SS Innovations International, Inc. | 50.00 | 2 | |
| MOVE | Corvex Inc. | 50.00 | 2 | |
| SNN | Smith & Nephew plc | 50.00 | 2 | |
| PYPD | PolyPid Ltd. | 50.00 | 2 | |
| MTLS | Materialise NV | 50.00 | 2 | |
| NDRA | ENDRA Life Sciences Inc. | 50.00 | 2 | |
| IART | Integra LifeSciences Holdings Corporation | 50.00 | 2 | |
| ELUTIA | ELUTIA | 50.00 | 2 |